Oniria Therapeutics, VHIO and ICIQ awarded over €1.7 million from Spanish Ministry of Science and Innovation to advance ONR-001 drug targeting resistant colon cancer

by ONIRIA Therapeutics

Biopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) will work together on the regulatory preclinical phas...

Read more

An international study shows that combining immunotherapy with chemotherapy improves survival in stomach cancer

by Instituto de Investigación Marqués de Valdecilla

The results confirm that combining durvalumab with FLOT (fluorouracilo, leucovorina, oxaliplatina y docetaxel) is not only effective but also safe for patients.

Read more

VIOLET Pharmaceuticals, the new spin-off of the Hospital del Mar Research Institute Barcelona, increases the effectiveness of immunotherapies for metastatic cancer

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

This spin-off of the Hospital del Mar Research Institute Barcelona seeks to make tumour cells visible by forcing them to overexpress the LCOR protein, which regulates tumour "visibility" by promoting ...

Read more

Mini-cólones bioartificiales para ver nacer el cáncer de colon en el laboratorio

by Professional Newco

El artículo del Dr. Francisco Lorenzo, científico de la Universidad de Salamanca y del Centro de Investigación del Cáncer (CSIC-USAL), publicado en Nature Protocols detalla por primera vez cómo g...

Read more

Results from IMMUNOMICS-VHIO platform’s first study demonstrate the efficacy of ultrasensitive liquid biopsy in predicting and monitoring immunotherapy response

by VHIO

Published today in Clinical Cancer Research, results from this project’s first study show that ultrasensitive circulating tumor DNA analysis can predict immunotherapy response in patients with advan...

Read more

A new study shows targeted immunotherapy halves metastasis risk in high-risk early HER2+ breast cancer

by Fundació Clínic per a la Recerca Biomèdica

The international DESTINY-Breast05 trial, published in The New England Journal of Medicine, demonstrates that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) reduces by half the risk of inv...

Read more

Investigadores del CIC abordan nuevas vías para profundizar en los mecanismos de acción de los fármacos contra el cáncer

by Professional Newco

El amplio mapa desarrollado de fármacos y genes diana, y el método innovador (denominado "farmaco-genómica") representan una herramienta prometedora para acelerar la identificación de nuevas diana...

Read more

La Aemps autoriza el primer ensayo clínico bajo el nuevo procedimiento de evaluación acelerada para oncología y enfermedades raras

by Farmaindustria

Este estudio de fase I/II en tumores sólidos se convierte en el primer ensayo de la industria farmacéutica autorizado en nuestro país bajo las nuevas guías fast track, con un proceso regulatorio q...

Read more

A new study reveals the essential role of galectin-9 in immune system activation

by CIC bioGUNE

A new study published in PNAS uncovers the essential role of galectin-9 (gal9) in orchestrating how dendritic cells activate T cells, revealing a previously unknown mechanism that could inspire next-g...

Read more

Double advance in ovarian cancer: attacking a pseudogene shrinks the tumour and paves the way for safer therapies

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

The IDIBELL-ICO study, in collaboration with the IJC, shows that the blockade of the pseudogene RPSAP52 in ovarian cancer reduces tumor growth without showing obvious signs of toxicity in preclinical ...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream